A University of Texas System patent describes new YAP1 degradation inducing proteolysis targeting chimeras (PROTACs) designed for use in the treatment of cancer.
Boomray Co. Ltd. has prepared and tested new peptide-drug conjugates comprising a radionuclide-labeled probe linked to a fibroblast activation protein α (FAP)-targeting peptide. They are reported to be useful for the diagnosis and treatment of cancer, inflammation, atherosclerosis, fibrosis and scars.
Sprint Bioscience AB has announced positive results from a preclinical proof-of-concept (POC) study performed within the company’s VRK1 program that showed that VRK1 inhibition selectively kills glioblastoma cells with low VRK2 levels, while cells with normal VRK2 levels are not affected.
Mestag Therapeutics Ltd. has raised a $40 million round from existing investors as it completes final preparations for its lead program MST-0312 to enter clinical development in mid-2026. MST-0312 is a bispecific antibody aimed at the lymphotoxin-β receptor (LTBR), which is essential for the development of lymphoid tissues.
Eisai Co. Ltd. has patented immunoconjugates comprising monoclonal antibodies targeting 5’-nucleotidase (CD73) covalently linked to cytotoxic drug. They are reported to be useful for the treatment of cancer.
Sunrise Oncology (Hong Kong) Ltd. has disclosed GTPase KRAS inhibitors in a recent patent. They are described as potentially useful for the treatment of cancer.
Avelos Therapeutics Inc. has identified substituted triazine compounds acting as ubiquitin carboxyl-terminal hydrolase 1 (USP1) inhibitors potentially useful for the treatment of cancer.
In a recent publication, researchers from Johnson & Johnson presented a bispecific antibody – JNJ-79032421 – targeting CD3 on T cells and the membrane-restricted, non-shed region of full-length mesothelin (MSLN) on cancer cells.
Akeso Inc.’s first-in-class trispecific antibody, AK-150, has received IND clearance from China’s National Medical Products Administration (NMPA) for clinical trials in patients with advanced solid tumors. Engineered using Akeso’s AI-driven drug discovery platform and its proprietary Tetrabody technology, AK-150 is a humanized anti-CSF-1R, ILT2 and ILT4 trispecific antibody that achieves multipathway blockade of both innate and adaptive immunity.
Enodia Therapeutics SAS has acquired Kezar Life Sciences Inc.’s assets from its Sec61-based discovery and development program, including clinical-stage KZR-261. Insights from Kezar’s Sec61-based programs will further strengthen Enodia’s core focus on Sec61-driven selectivity for targeting protein degradation.
RSS
